Information Provided By:
Fly News Breaks for May 3, 2019
ABMD
May 3, 2019 | 08:49 EDT
Weakness in Abiomed's fiscal Q4 had been well telegraphed but was still worse than expected, Jefferies analyst Raj Denhoy tells investors in a research note. However, he believes issues with Impella use are being addressed and points out that April saw an uptick from March. The company's fiscal 2020 guidance of 17%-23% "seems doable," adds Denhoy. He lowered his price target for the shares to $330 from $460 and keeps a Buy rating on the name. The analyst believes now is the time to own Abiomed.
News For ABMD From the Last 2 Days
There are no results for your query ABMD